Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry J Byrne

Showing results (1-10 of 245) with videos related to

Pageof 25
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 2, 2013
Pathway for approval of a gene therapy orphan product: treading new groundBarry J Byrne
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 28, 2019
Neuromuscular Gene Therapy: Catching the Wave of Positive Early Studies Is Expected to Crest in Product ApprovalsBarry J Byrne
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 6, 2018
Safety First: Perspective on Patient-Centered Development of AAV Gene Therapy ProductsBarry J Byrne
Human Gene Therapy|February 14, 2012
A new approach to winning: insulin-like growth factor-I signaling in competitive sportBarry J Byrne
Human Gene Therapy|April 9, 2010
Innovative vector design: cross-packaged, self-complementary and now trans-splicing AAV vectorsBarry J Byrne
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 3, 2012
Signs of progress in gene therapy for muscular dystrophy also warrant cautionHansell H Stedman, Barry J Byrne
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 28, 2011
AAV vectors for cardiac gene transfer: experimental tools and clinical opportunitiesChristina A Pacak, Barry J Byrne
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 24, 2021
Considerations for Systemic Use of Gene TherapyBarry J Byrne, Manuela Corti, Francesco Muntoni
Current Molecular Medicine|April 13, 2002
Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease)Nina Raben, Paul Plotz, Barry J Byrne
Human Gene Therapy|July 3, 2009
Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studiesNathalie Clément, David R Knop, Barry J Byrne
Pageof 25

Showing results (1-10 of 245) with videos related to

Sort By:
Pageof 25
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 2, 2013
Pathway for approval of a gene therapy orphan product: treading new groundBarry J Byrne
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 28, 2019
Neuromuscular Gene Therapy: Catching the Wave of Positive Early Studies Is Expected to Crest in Product ApprovalsBarry J Byrne
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 6, 2018
Safety First: Perspective on Patient-Centered Development of AAV Gene Therapy ProductsBarry J Byrne
Human Gene Therapy|February 14, 2012
A new approach to winning: insulin-like growth factor-I signaling in competitive sportBarry J Byrne
Human Gene Therapy|April 9, 2010
Innovative vector design: cross-packaged, self-complementary and now trans-splicing AAV vectorsBarry J Byrne
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 3, 2012
Signs of progress in gene therapy for muscular dystrophy also warrant cautionHansell H Stedman, Barry J Byrne
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 28, 2011
AAV vectors for cardiac gene transfer: experimental tools and clinical opportunitiesChristina A Pacak, Barry J Byrne
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 24, 2021
Considerations for Systemic Use of Gene TherapyBarry J Byrne, Manuela Corti, Francesco Muntoni
Current Molecular Medicine|April 13, 2002
Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease)Nina Raben, Paul Plotz, Barry J Byrne
Human Gene Therapy|July 3, 2009
Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studiesNathalie Clément, David R Knop, Barry J Byrne
Pageof 25